Seminars in Perinatology
Volume 31, Issue 4 , Pages 243-249 , August 2007

Prothrombotic Risk Factors in the Evaluation and Management of Perinatal Stroke

References 

  1. DeVeber G. Risk factors for childhood stroke: little folks have different strokes!. Ann Neurol. 2004;53:149–150
  2. Lynch JK, Nelson KB. Epidemiology of perinatal stroke. Curr Opin Pediatr. 2001;13:499–505
  3. deVeber G The Canadian Pediatric Ischemic Stroke Study Group. Canadian paediatric ischemic stroke registry: analysis of children with arterial ischemic stroke. [abstract] Ann Neurol. 2000;48:526
  4. Kurnik K, Kosch A, Strater R, et al. Recurrent thromboembolism infants and chidlren suffering from symptomatic neonatal arterial stroke. Stroke. 2003;34:2887–2893
  5. Chabrier S, Buchmuller A. Specificities of the neonatal stroke. Stroke. 2003;34:2893–2894
  6. Gunther G, Junker R, Strater R, et al. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke. 2000;31:2437–2441
  7. Mercuri E, Cowan F, Gupte G, et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics. 2001;107:1400–1404
  8. Curry CJ, Roeder ER. Thrombophilic factors in neonatal stroke. Pediatr Res. 1999;45:340A
  9. Simchen M, Goldstein G, Lubetsky A, et al. Perinatal ischemic stroke and the incidence of maternal and neonatal thrombophlia. Am J Obstet Gynecol. 2006;195:S209
  10. Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke. 2000;31:1283–1288
  11. Nowak-Göttl U, Sträter R, Junker R, et al. Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood. 1999;94:3678–3682
  12. Lynch JK, Nelson KB, Curry CJ, et al. Cerebrovascular disorders in children with the factor V Leiden mutation. J Child Neurol. 2001;16:735–744
  13. Verdu A, Cazorla MR, Granados MA, et al. Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation. Pediatr Neurol. 2001;24:69–71
  14. Akar N, Akar E, Ozel D, et al. Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res. 2001;102:115–120
  15. Ganesan V, McShane MA, Liesner R, et al. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry. 1998;65:508–511
  16. McColl MD, Chalmers EA, Thomas A, et al. Factor V Leiden, prothrombin 20210G A, and the MTHFR C677T mutations in childhood stroke. Thromb Haemost. 1999;81:690–694
  17. Zenz W, Bodo Z, Plotho J, et al. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost. 1998;80:763–766
  18. Andrew ME, Monagle P, deVeber G, et al. Thromboembolic disease and antithrombotic therapy in newborns hematology. American Society of Hematology Education Program. 2001;358–374
  19. Strater R, Vielhaber H, Kassenbohmer R, et al. Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin: a prospective ESPED survey. Eur J Pediatr. 1999;158(suppl 3):S122–S125
  20. Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001;98:2980–2987
  21. Israels SJ, Seshia SS. Childhood stroke associated with familial protein C or S deficiency. J Pediatr. 1987;111:562–564
  22. Simioni P, Battistella PA, Drigo P, et al. Childhood stroke associated with familial protein S deficiency. Brain Dev. 1994;16:241–245
  23. Brenner B, Fishman A, Goldsher D, et al. Cerebral thrombosis in a newborn with a congenital deficiency of antithrombin III. Am J Hematol. 1988;27:209–211
  24. Mayer SA, Sacco RL, Hurlet-Jensen A, et al. Free protein S in acute ischemic stroke: a case control study. Stroke. 1993;24:224–227
  25. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Ped Hematol Oncol. 1990;12:95–104
  26. Dawson S, Hamsten A, Wiman B, et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11:183–190
  27. Nowak-Göttl U, Strater R, Kosch A, et al. The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children (Childhood Stroke Study Group). Eur J Haematol. 2001;66:57–62
  28. Akar N, Akar E, Yilmaz E, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. J Child Neurol. 2001;16:294–295
  29. Cardo E, Vilaseca MA, Campistol J, et al. Evaluation of hyperhomocysteinemia in children with stroke. Eur J Paediatr Neurol. 1999;3:113–117
  30. van Beynum IM, Smeitink JA, den Heijer M, et al. Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation. 1999;99:2070–2072
  31. Cardo E, Monros E, Colome C, et al. Children with stroke: polymorphism of the MTHFR gene, mild hyperhomocysteinemia, and vitamin status. J Child Neurol. 2000;15:295–298
  32. Prengler M, Sturt N, Krywawych S, et al. Homozygous thermolabile variant of the methylenetetrahydrofolate reductase gene: a potential risk factor for hyperhomocysteinaemia (CVD, and stroke in childhood). Dev Med Child Neurol. 2001;43:220–225
  33. Rook JL, Nugent DJ, Young G. Pediatric stroke and methylenetetrahydrofolate reductase polymorphisms. J Ped Hematol Oncol. 2005;27:590–593
  34. Hogeveen M, Blom HJ, Van Amerongen M, et al. Hyperhomocysteinemia as risk factor for ischemic and hemorrhagic stroke in newborn infants. J Pediatr. 2002;141:429–431
  35. deVeber G, Monagle P, Chan A, et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol. 1998;55:1539–1543
  36. Golomb MR, MacGregor DL, Domi T, et al. Presumed pre- or perinatal arterial ischemic stroke: risk factors and outcomes. Ann Neurol. 2001;50:163–168
  37. Silver RK, MacGregor SN, Pasternak JF, et al. Fetal stroke associated with elevated maternal anticardiolipin antibodies. Obstet Gynecol. 1992;80:497–499
  38. Heller C, Becker S, Scharrer I, et al. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur J Pediatr. 1999;158(suppl 3):S117–S121
  39. Livingston JC, Barton JR, Park V, et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol. 2001;185:153–157
  40. Gerhardt A, Goecke TW, Beckmann MW, et al. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thrombos Haemostas. 2005;3:686–691
  41. Redline RW. Thrombophlia and placental pathology. Clin Obstet Gynecol. 2006;49:885–894
  42. Roberts D, Schwartz RS. Clotting and hemorrhage in the placenta: a delicate balance. New Eng J Med. 2002;347:57–59
  43. Kenet G, Kircham F, Niederstadt T, et al. European collaborative paediatic database on cerebral venous thrombosis: risk factors for recurrent venous thromboembolism. Blood. 2006;106:1629
  44. McKinden , Anderson PE. Early cognitive outcome after neonatal stroke. Stroke. 2006;37:641
  45. Waheed S, Myers G, Guillet R. Neurodevelopmental outcome is favorable in neonatal cerebral stroke. Pediatr Res. 1998;43:325

PII: S0146-0005(07)00066-3

doi: 10.1053/j.semperi.2007.06.001

Seminars in Perinatology
Volume 31, Issue 4 , Pages 243-249 , August 2007

Article Tools

* Image Usage & Resolution